Radiology Doctors in Quincy, IL Accepting Medicare

5 Radiology doctors found. Showing 1 - 5

Dr. Robert C Johnson, MD Radiology - Radiation Oncology Medicare: May Accept Medicare Assignments Practice Location: 1005 Broadway St, Quincy, IL 62301 Phone: 217-223-8400    Fax: 217-223-7327

Dr. Gerald T Riley, M.D. Radiology - Diagnostic Radiology Medicare: Accepting Medicare Assignments Practice Location: 1025 Maine St, Quincy, IL 62301 Phone: 217-222-6550

Robert Haag, MD Radiology - Diagnostic Radiology Medicare: Accepting Medicare Assignments Practice Location: 1025 Maine St, Quincy, IL 62301 Phone: 217-222-6550

Dr. Young Woo Yu, M.D. Radiology - Radiation Oncology Medicare: Not Enrolled in Medicare Practice Location: Broadway At 11th Street, Blessing Hospital, Quincy, IL 62301 Phone: 217-223-8400

Mark Sunung Khil, M.D. Radiology - Radiation Oncology Medicare: May Accept Medicare Assignments Practice Location: 1005 Broadway St, Quincy, IL 62301 Phone: 217-277-3500    Fax: 217-223-7327

News Archive

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010

Genmab A/S announced today that data from the pivotal trial of zalutumumab in refractory head and neck cancer patients will be presented today at the 2010 American Society of Clinical Oncology Annual Meeting, which will be held June 1-8 in Chicago, Illinois. This is the first controlled study to demonstrate that an EGFr-targeted antibody given as monotherapy induces a clinically meaningful improvement in progression free survival in patients with refractory head and neck cancer who have failed platinum-based chemotherapy.

RhoGDI2 protein helps prevent bladder cancer metastasis to the lungs

The diagnosis of localized bladder cancer carries an 80 percent five-year survival rate, but once the cancer spreads, the survival rate at even three years is only 20 percent. A major study published today in the Journal of Clinical Investigation not only shows how bladder cancer metastasizes to the lungs but pinpoints a method for stopping this spread.

Liquid biopsies that enable screening, early detection of cancer attract attention of investors

Interest is high in the development of blood-based tests that can be used to screen individuals for cancer. That isn't new, liquid biopsy industry has attracted attention and investment for the past few years.

Read more Medical News

› Verified 5 days ago